{
    "0000229950": {
        "patient_name": "",
        "total_visits": 1,
        "visits": [
            {
                "visit_index": 1,
                "visit_id": "0000229950",
                "enter_time": "2015-11-06 14:48:00",
                "source_file": "/Users/yannan/PycharmProjects/Rmaintain/1151005698843348992.json",
                "features": {
                    "continuous_features": {
                        "最大病灶cm (首次治疗)": {
                            "value": 3.0,
                            "evidence": "大小约3cm*2cm*2cm"
                        },
                        "SUVmax (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "启动一线治疗年龄（一般60为cutoff）": {
                            "value": 55.0,
                            "evidence": "2013年4月11日给予R-CHOP方案"
                        },
                        "一线治疗时累及淋巴结区域数目（大于等于5预后不良）": {
                            "value": null,
                            "evidence": ""
                        },
                        "LDH (首次治疗) >240是预后不良因素": {
                            "value": null,
                            "evidence": ""
                        },
                        "β2微球蛋白β2-MG (首次治疗) >3是预后不良因素": {
                            "value": null,
                            "evidence": ""
                        },
                        "WBC (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "HGB (首次治疗) <120是预后不良因素": {
                            "value": null,
                            "evidence": ""
                        },
                        "PLT (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "单核细胞绝对值 (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "淋巴细胞绝对值 (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "淋巴单核细胞比 (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        }
                    },
                    "categorical_features": {
                        "性别 (0:女; 1:男)": {
                            "value": "1",
                            "evidence": "exit_record.sex: 男"
                        },
                        "一线治疗时病理分级（绝大多数是1-2级和3a级，少数3b级和转化为大B细胞的）": {
                            "value": null,
                            "evidence": ""
                        },
                        "治疗时ECOG（体力评分，一般>2是预后不良因素）": {
                            "value": null,
                            "evidence": ""
                        },
                        "治疗时B症状(0:无; 1:有)": {
                            "value": "0",
                            "evidence": "无发热"
                        },
                        "首次开始治疗前分期（一般1-2称为局限期, 3-4进展期）": {
                            "value": null,
                            "evidence": ""
                        },
                        "治疗时是否骨髓受累（骨髓穿刺阳确，有是预后不良因素）": {
                            "value": "0",
                            "evidence": "未见淋巴瘤细胞侵润"
                        },
                        "治疗时单个淋巴结是否大于6cm（大于6预后不良因素）": {
                            "value": "0",
                            "evidence": "大小约3cm*2cm*2cm"
                        },
                        "分类1(1-chop;2-fc;3-rchop;4-rfc;5-cvp;6-rcvp;7-放疗; 8-R单药; 9-放化疗; 10-RB;11-GCHOP;12-WW;13-姑息对症)": {
                            "value": "3",
                            "evidence": "R-CHOP方案"
                        },
                        "评效分组1": {
                            "value": null,
                            "evidence": ""
                        },
                        "启动一线治疗后反应 (新补充)": {
                            "value": "好转",
                            "evidence": "病情好转出院"
                        }
                    }
                }
            }
        ]
    },
    "all_visits": {
        "patient_name": "",
        "total_visits": 1,
        "visits": [
            {
                "visit_index": 1,
                "visit_id": "all_visits_all_visits",
                "enter_time": "",
                "source_file": "/Users/yannan/PycharmProjects/Rmaintain/all_visits.json",
                "features": {
                    "continuous_features": {
                        "最大病灶cm (首次治疗)": {
                            "value": 3.0,
                            "evidence": "大小约3cm*2cm*2cm"
                        },
                        "SUVmax (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "启动一线治疗年龄（一般60为cutoff）": {
                            "value": 57.0,
                            "evidence": "患者男,57岁"
                        },
                        "一线治疗时累及淋巴结区域数目（大于等于5预后不良）": {
                            "value": null,
                            "evidence": ""
                        },
                        "LDH (首次治疗) >240是预后不良因素": {
                            "value": null,
                            "evidence": ""
                        },
                        "β2微球蛋白β2-MG (首次治疗) >3是预后不良因素": {
                            "value": null,
                            "evidence": ""
                        },
                        "WBC (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "HGB (首次治疗) <120是预后不良因素": {
                            "value": null,
                            "evidence": ""
                        },
                        "PLT (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "单核细胞绝对值 (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "淋巴细胞绝对值 (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "淋巴单核细胞比 (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        }
                    },
                    "categorical_features": {
                        "性别 (0:女; 1:男)": {
                            "value": "1",
                            "evidence": "患者男"
                        },
                        "一线治疗时病理分级（绝大多数是1-2级和3a级，少数3b级和转化为大B细胞的）": {
                            "value": null,
                            "evidence": ""
                        },
                        "治疗时ECOG（体力评分，一般>2是预后不良因素）": {
                            "value": null,
                            "evidence": ""
                        },
                        "治疗时B症状(0:无; 1:有)": {
                            "value": "0",
                            "evidence": "无发热"
                        },
                        "首次开始治疗前分期（一般1-2称为局限期, 3-4进展期）": {
                            "value": null,
                            "evidence": ""
                        },
                        "治疗时是否骨髓受累（骨髓穿刺阳确，有是预后不良因素）": {
                            "value": "0",
                            "evidence": "未见淋巴瘤细胞侵润"
                        },
                        "治疗时单个淋巴结是否大于6cm（大于6预后不良因素）": {
                            "value": "0",
                            "evidence": "大小约3cm*2cm*2cm"
                        },
                        "分类1(1-chop;2-fc;3-rchop;4-rfc;5-cvp;6-rcvp;7-放疗; 8-R单药; 9-放化疗; 10-RB;11-GCHOP;12-WW;13-姑息对症)": {
                            "value": "3",
                            "evidence": "R-CHOP方案"
                        },
                        "评效分组1": {
                            "value": null,
                            "evidence": ""
                        },
                        "启动一线治疗后反应 (新补充)": {
                            "value": null,
                            "evidence": ""
                        }
                    }
                }
            }
        ]
    },
    "features_config": {
        "patient_name": "",
        "total_visits": 1,
        "visits": [
            {
                "visit_index": 1,
                "visit_id": "features_config_features_config",
                "enter_time": "",
                "source_file": "/Users/yannan/PycharmProjects/Rmaintain/features_config.json",
                "features": {
                    "continuous_features": {
                        "最大病灶cm (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "SUVmax (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "启动一线治疗年龄（一般60为cutoff）": {
                            "value": null,
                            "evidence": ""
                        },
                        "一线治疗时累及淋巴结区域数目（大于等于5预后不良）": {
                            "value": null,
                            "evidence": ""
                        },
                        "LDH (首次治疗) >240是预后不良因素": {
                            "value": null,
                            "evidence": ""
                        },
                        "β2微球蛋白β2-MG (首次治疗) >3是预后不良因素": {
                            "value": null,
                            "evidence": ""
                        },
                        "WBC (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "HGB (首次治疗) <120是预后不良因素": {
                            "value": null,
                            "evidence": ""
                        },
                        "PLT (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "单核细胞绝对值 (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "淋巴细胞绝对值 (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        },
                        "淋巴单核细胞比 (首次治疗)": {
                            "value": null,
                            "evidence": ""
                        }
                    },
                    "categorical_features": {
                        "性别 (0:女; 1:男)": {
                            "value": null,
                            "evidence": ""
                        },
                        "一线治疗时病理分级（绝大多数是1-2级和3a级，少数3b级和转化为大B细胞的）": {
                            "value": null,
                            "evidence": ""
                        },
                        "治疗时ECOG（体力评分，一般>2是预后不良因素）": {
                            "value": null,
                            "evidence": ""
                        },
                        "治疗时B症状(0:无; 1:有)": {
                            "value": null,
                            "evidence": ""
                        },
                        "首次开始治疗前分期（一般1-2称为局限期, 3-4进展期）": {
                            "value": null,
                            "evidence": ""
                        },
                        "治疗时是否骨髓受累（骨髓穿刺阳确，有是预后不良因素）": {
                            "value": null,
                            "evidence": ""
                        },
                        "治疗时单个淋巴结是否大于6cm（大于6预后不良因素）": {
                            "value": null,
                            "evidence": ""
                        },
                        "分类1(1-chop;2-fc;3-rchop;4-rfc;5-cvp;6-rcvp;7-放疗; 8-R单药; 9-放化疗; 10-RB;11-GCHOP;12-WW;13-姑息对症)": {
                            "value": null,
                            "evidence": ""
                        },
                        "评效分组1": {
                            "value": null,
                            "evidence": ""
                        },
                        "启动一线治疗后反应 (新补充)": {
                            "value": null,
                            "evidence": ""
                        }
                    }
                }
            }
        ]
    }
}